Clinical and Economic Impact of Glatiramer Acetate Versus Beta Interferon Therapy Among Patients With Multiple Sclerosis in a Managed Care Population
In addition to these mechanistic differences, data from clinical trials and postmarketing surveillance studies suggest that glatiramer acetate may have several distinct advantages relative to the interferons, including a relatively mild side-effect profile allowing for less use of concomitant medications such as acetaminophen and NSAIDs, lack of neutralizing antibodies, and reduced need for laboratory monitoring. 25 These advantages may be associated with greater durability of treatment, better outcomes, and reduced utilization and costs relative to interferon therapy. Patterns of pharmacotherapy as well as the costs and effects of these 3 medications have never been compared under conditions of typical clinical practice, however. To address these needs, an examination of the impact of GA on the utilization and costs of MS-related care relative to that of beta interferon therapy was undertaken, using data from a proprietary database.
■■ Methods Overview
Data for this study were obtained on all patients with one or more institutional or provider claims with a listed diagnosis of MS (ICD-9-CM 340) who were in the database between January 1, 1996, and June 30, 2001 . Patients were then classified into 3 treatment groups based on data on the first paid pharmacy claim observed during the study period (i.e., GA, 1A, or 1B). Each patient was assigned an "index date" based on the date of the first prescription for immunomodulatory therapy. A variety of measures were then compared during the "follow-up period" (i.e., beginning with the index date) between patients in the 3 treatment groups, including the cumulative incidence of relapses, time to first relapse, and the mean number of relapses, as well as the utilization and costs of selected MS-related medications and health care services. Because the duration of eligibility for health and drug benefits during the follow-up period differed by patient, annualization as well as techniques of survival analysis (i.e., examination of data according to time observed without any specific threshold) were employed to estimate the above-described measures.
Data Source
Data were obtained from the proprietary database, which is comprised of fully adjudicated medical and pharmaceutical claims for nearly 27 million unique patients from 43 health plans across the United States. The database includes both inpatient and outpatient diagnoses (in ICD-9-CM format) and procedures (in CPT-4 and HCPCS formats) as well as both community pharmacy and mail-order prescription records; available data on prescription records include the National Drug Code (NDC) as well as days supplied and quantity dispensed (for a subgroup of datasets). Both paid and charge amounts are available for all services rendered as well as dates of service for all claims. Additional data elements include demographic variables (age, gender, geographic region), plan type (e.g., HMO, PPO), payer type (e.g., commercial, self-pay), provider specialty, and start and stop dates for plan enrollment.
Records in the database are representative of the national managed care population on a variety of demographic measures, including geographic region, age, gender, and plan type. The data are also longitudinal, with an average member enrollment time of 2 years. Only health plans submitting data for all members are included in the database, ensuring complete data capture and unbiased samples. Data contributions are also subjected to a series of quality checks to ensure a standardized format and minimal error rates.
Measures
Measures of interest in these analyses included the incidence of all relapses as well as utilization and costs of MS-related medications and health care services during the period of follow-up. MS relapses are typically defined using one of several disability or symptom scales.
26, 27 Analyses of claims data are limited, however, to measures that would be associated with care-seeking behavior. An operational definition of relapses was therefore employed and was defined on the basis of either (a) an inpatient claim (hospitalization) with a listed principal diagnosis of MS or (b) a claim for an outpatient visit with a listed diagnosis of MS in combination with a pharmacy or medical claim (within 7 days after the visit) for one of the following: intravenous methylprednisolone or corticotrophin or oral methylprednisolone, prednisone, prednisolone, or dexamethasone. If multiple claims were present within a 30-day window, this was treated as a single relapse event; the first available service date within such a grouping was deemed to be the relapse date.
Medications , and other hospital outpatient visits), and hospitalizations for MS. Inpatient and outpatient services were deemed to be MS-related based on a relevant listed diagnosis (principal or secondary); lab tests were tallied regardless of diagnosis. Costs of all relevant medications and services also were assessed. A health plan perspective was adopted in these analyses; cost estimates were therefore based on the amount paid (less patient copayments and deductibles) for relevant claims.
Analyses
Primary analyses were conducted on an intent-to-treat basis; all patients with an MS diagnosis and receipt of immunomodula-tory therapy were therefore included in these analyses. Additional analyses focused attention on important subgroups, including patients newly starting immunomodulatory therapy as well as those remaining on only a single immunomodulatory medication (i.e., exclusive of switch or add-on therapy). New starts were determined based on the absence of any pharmacy claims for immunomodulatory therapy during a 9-month "pretreatment" period (i.e., prior to the first claim for the medication of interest).
Patients in the 3 treatment groups were first compared with respect to a variety of demographic and clinical characteristics, including age, gender, duration of follow-up, number of relapses and total costs during the pretreatment period (new starts only), type of health plan (e.g., PPO, HMO, fee-for-service), physician specialty, and geographic region.
Estimated propensity scores for use of immunomodulatory therapy also were calculated as a measure of patient severity of illness and disease progression. These scores represent a given patient' s probability, or "propensity," of receiving a given treatment option and are calculated by summing coefficient values for a list of potential confounding variables. Use of these scores confers the advantage of having a single estimate available to adjust for confounding (i.e., effects on the findings of interest other than treatment effect) in any multivariate analysis, and have been widely used in clinical and economic research examining causal effects and in comparisons of nonrandomized groups. 28, 29 In this case, the outcome of interest was the probability of use of any of the 3 immunomodulatory medications of interest. Covariates (i.e., potentially confounding variables) were introduced to the model using stepwise logistic regression techniques; those achieving significance at a level of P<.10 were retained. In the final model, age, geographic region, a flag for the presence of at least one relapse during the pretreatment and follow-up periods, physi- 
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Therapy changes (%):
Add/switch to glatiramer acetate -7.1 5.5 <.001 Add/switch to interferon beta 1a 0.0 -0.0 Add/switch to interferon beta 1b 0.0 2.8 - Between-group variance in all demographic and clinical measures was assessed using analysis of variance (ANOVA) for continuous variables and an overall chi-square test statistic for proportions.
The cumulative incidence of relapse was presented descriptively as a rate per 1,000 person-years, as was the time to first relapse during follow-up. Hazard rates (i.e., measurement of the increased risk) for the risk of relapse at one year were estimated using a Cox proportional hazards model, controlling for treatment group, propensity score, and censoring (i.e., termination of follow-up at less than one year). The number of relapses per patient also was calculated using a variety of univariate statistics and was compared using ANOVA.
Utilization and costs of MS-related medications and health care services were calculated using overall group means and standard deviations and analyzed using ANOVA techniques. In addition, multivariate analyses of cost were undertaken based on the presence of significant differences in demographic and clinical characteristics between treatment groups. Specifically, an accelerated failure time model, which produces estimates of parametric regression models with censored survival data using the maximum likelihood method, was employed to estimate one-year measures of cost. 30 Costs were log-transformed prior to analysis to account for data skewness; independent variables included age, sex, and propensity score (inclusion of age both in the propensity score and as a separate covariate allowed for greater precision in generating maximum-likelihood estimates than the propensity score alone).
Relapse rates as well as measures of utilization and cost were generated for prespecified subgroups, including patients newly starting immunomodulatory therapy and those remaining on a single immunomodulatory medication only.
All analyses were conducted using Statistical Analysis Software (SAS), version 8.1 (SAS Institute, Cary, NC).
■■ Results
Patient Characteristics
Demographic and clinical characteristics of the study sample are presented in Table 1 . A total of 8,457 patients were selected for inclusion in these analyses (n=1,674, 5,031, and 1,752 for GA, 1A, and 1B, respectively). The mean age for the sample was 42 years; approximately 75% were female. Both age and gender differed significantly (P<.001) by treatment group. The mean duration of follow-up (approximately 520 days or 17.3 months for the overall sample) also differed significantly (P<.001) by group and was substantially lower among patients receiving GA versus those receiving the other drugs; this phenomenon is likely due to GA' s later introduction to the MS marketplace. As a result, unadjusted information on relapse, utilization, and costs is presented on an annualized basis.
Mean propensity scores for use of immunomodulatory therapy were highest for GA patients (0.2631 versus 0.2575 and 0.2431 for 1A and 1B, respectively). Significant (P<.001) differences also were noted for plan type, physician specialty, and geographic region. Patients receiving GA were more likely to be members of more managed plans (e.g., HMO, PPO), while those receiving 1A and 1B were somewhat more likely to be in less managed environments (e.g., indemnity, POS). Nearly two thirds of patients receiving immunomodulatory therapy were managed by a neurologist.
Among patients receiving GA, there were no switches to or polytherapy with either of the beta interferons. However, a total of 498 (9.9%) and 96 (5.5%) 1A and 1B patients, respectively, switched or added therapy during follow-up. The majority of these therapy changes involved GA (i.e., either as switch or addon therapy).
Of all identified patients receiving immunomodulatory therapy, a total of 3,161 (37.4%) were identified as new starts (i.e., based on a 9-month pretreatment period with no use of such medication). Among these patients, the mean (±SD) number of relapses during pretreatment did not significantly differ by treatment group (0. 22 
MS-related Resource Utilization
Utilization of MS-related medications and health care services is presented in Table 3 . Other than study therapy, most other medications were used infrequently. The most commonly used medications were antidepressants (mean number of prescriptions per year: 2.3 to 2.5), skeletal muscle relaxants (1.6 to 1.9), and adrenals and combinations (1.3 to 1.7). Surprisingly, while periodic laboratory monitoring is recommended for the beta interferons but not for GA, the use of selected tests was infrequent among all groups and did not materially differ between them. Utilization of other services also is presented in Table 3 .
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Use of physician office and other hospital outpatient services was highest among 1A patients, while use of inpatient services (i.e., for treatment of relapse and other MS-related services) was slightly higher among GA patients.
MS-related Costs
Annualized costs of medications and health care services are presented in Table 4 . Mean (±SD) costs of all MS-related medications were lowest for GA ($7,256 [±$5,727]), followed by 1A ($7,992 [±$6,219) and 1B ($8,083 [±$6,260]); these differences were statistically significant (P<.001). GA' s lower costs relative to the beta interferons were manifested almost entirely in lower acquisition costs for study therapy. Costs of outpatient services were similar for GA and 1A and slightly lower for 1B. Costs for inpatient care were lowest for 1A relative to the other 3 groups; neither outpatient nor inpatient costs differed statistically. Total costs of care averaged $9,522 (±$9,706), $9,957 (±$9,083), and $10,185 (±$9,526) for GA, 1A, and 1B, respectively (P=.004), which again primarily reflects differences in immunomodulatory drug costs. Findings persisted in multivariate analyses of cost; differences were mitigated somewhat between GA and 1A, while differences between GA and 1B were more marked ($10,879, $10,968, and $11,619 for GA, 1A, and 1B, respectively).
Additional Analyses
Among patients newly starting immunomodulatory therapy, the incidence of all relapses during follow-up was 17% to 22% higher with the beta interferons relative to GA (data not shown); while the one-year risk of relapse did not differ between 1A and GA, the risk among 1B patients was nearly double that of GA (HR=1.856, P=.020). Findings were similar among patients who did not switch or add on therapy (HR=1.389 for 1B relative to GA, P=.029). Not surprisingly, in the cohort of patients newly starting immunomodulatory therapy, utilization of health care services was somewhat lower than for the entire cohort, particularly with respect to inpatient care; utilization of MS-related medications was similar, however (data not shown). On an annualized basis, total costs for GA patients remained lower than for 1A and 1B patients ( 
■■ Discussion
To examine the impact of use of GA therapy on relapse rates as well as MS-related resource utilization and costs relative to that among patients receiving beta interferon 1A or 1B, we undertook a retrospective analysis of medical and pharmacy claims data among a cohort of MS patients receiving these medications. Data on the incidence of relapses was examined for these patients, as was information on the utilization and costs of MSrelated medications, outpatient services, and inpatient care. The results of this study indicate that use of GA therapy in patients with MS results in a lower rate of relapse relative to those receiving either beta interferon therapies. In addition, therapy with GA appeared to be more "durable" than that of the beta interferons-patients receiving the former did not switch or add on immunomodulatory therapy, while nearly 10% of those receiving beta interferon therapy did experience a therapy change. Finally, total costs of MS-related care were reduced by $400 to $700 among GA patients relative to the beta interferons; findings persisted in multivariate analyses controlling for age, sex, and propensity scores for immunomodulatory therapy.
A number of previous studies have evaluated the cost-effectiveness of immunomodulatory therapy in multiple sclerosis. [31] [32] [33] [34] [35] [36] [37] Without exception, all of the existing studies have compared the costs and effects of beta interferon or GA therapy to those among patients receiving therapy for symptomatic relief only. To the best of our knowledge, this is the first such study to com- [32] [33] [34] [35] [36] These findings are at odds with current clinical opinion, however, which suggests that immunomodulatory agents should receive widespread use among patients with MS and should be used early in the course of the disease.
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■■ Limitations
We note some limitations of our analysis. First, our comparison was limited to patients receiving immunomodulatory therapy, as noted above. In reality, many MS patients are still treated with only medications for the symptoms; in fact, nearly 75% of the patients with MS diagnoses in our database did not receive immunomodulatory medications. Examination of the economic and clinical impact of immunomodulatory medications as a group in an MS population requires comparison to a comparable population that did not receive these medications. Such an analysis is likely to be problematic in a retrospective database, however, as patients not receiving immunomodulatory therapy are historically likely to be at an earlier stage of disease progression and therefore less severely ill.
In addition, as with all quasi-experimental research based on retrospective data, we cannot rule out the possibility that our findings may have been influenced by differences in disease severity, duration of illness, and rate of disease progression between the 3 treatment groups that were the focus of our analysis. While it is true that these important factors are not detectable in any detailed way in claims data, the use of a propensity score in this circumstance does provide a method to control for differences in patient, physician, or health plan characteristics between patient groups. Indeed, our findings were nearly identical among the subgroup of patients newly starting immunomodulatory therapy (who would be expected to be more comparable in terms of disease progression and/or severity) as well as those remaining on a single agent during followup. Perhaps most importantly, the direction of these findings was unchanged in multivariate analyses controlling for propensity for immunomodulatory therapy and other covariates that were detectable in this particular data source.
In addition, our measure of relapse was limited to utilization proxies only; this definition was likely insensitive or conservative since overall annualized relapse rates (0.24 to 0.31 per patient) are lower than those reported in clinical studies. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] 39 However, this effect was equally distributed across treatment groups and therefore likely affects only the magnitude (and not the direction) of our findings. While GA appeared to confer some benefit with regard to relapse as measured in our study, it should be noted that differences in risk and time to event were moderate (albeit statistically significant); perceptions as to the clinical significance of these differences will vary.
Finally, we could not measure the impact of these medications on important intermediate and qualitative outcomes such as lesion detection on magnetic resonance imaging, disability status, or function. Measurement of clear differences in effectiveness will only come through the conduct of randomized, head-to-head clinical trials of these agents, where levels of disease severity are comparable at the time of enrollment.
■■ Conclusion
Our findings suggest that use of glatiramer acetate may reduce rates of relapse as well as levels of MS-related utilization and costs relative to the beta interferons; further study is required, however, to document these benefits in a definitive manner. Our results are likely to be of interest to health care payers and providers as well as patients with multiple sclerosis who may be candidates for immunomodulatory therapy. 
DISCLOSURES
